ArticleBMC cancer2016
Etoposide damages female germ cells in the developing ovary.
Article in BMC cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 28 citations in OpenAlex.
- Reproductive and sexual sequelae of neuroendocrine tumour therapies: an under-recognised challenge.Endocrine-related cancer · 2026Review
- A versatile cohesion manipulation system probes female reproductive age-related egg aneuploidy.Nature aging · 2025Article
- The impact ofHuman reproduction open · 2025Review
- In vitro exposure to benzo[a]pyrene damages the developing mouse ovary.Reproduction & fertility · 2023Article
- Effects of chemotherapy on ovaries of pregnant mice.Archives of gynecology and obstetrics · 2023Article
- Effect of Neuroendocrine Neoplasm Treatment on Human Reproductive Health and Sexual Function.Journal of clinical medicine · 2022Review
- Haemophagocytic lymphohistiocytosis in pregnancy.Obstetric medicine · 2022Review
- The Role of ROS as a Double-Edged Sword in (In)Fertility: The Impact of Cancer Treatment.Cancers · 2022Review
- Management of hemophagocytic lymphohistiocytosis in pregnancy: Case series study and literature review.The journal of obstetrics and gynaecology research · 2022Review
- Case report and literature review: Hemophagocytic lymphohistiocytosis in a pregnant woman with systemic lupus erythematosus withFrontiers in oncology · 2022Article
- Hemophagocytic lymphohistiocytosis during pregnancy: a review of the literature in epidemiology, pathogenesis, diagnosis and treatment.Orphanet journal of rare diseases · 2021Review
- Improved preservation of ovarian tissue morphology that is compatible with antigen detection using a fixative mixture of formalin and acetic acid.Human reproduction (Oxford, England) · 2021Article
- Reduced retinoic acid synthesis accelerates prophase I and follicle activation.Reproduction (Cambridge, England) · 2020Article
- Article
- Dazl determines primordial follicle formation through the translational regulation of Tex14.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2019Article
- Requirement for etoposide in the treatment of pregnancy related hemophagocytic lymphohistiocytosis: a multicenter retrospective study.Orphanet journal of rare diseases · 2019Article
- Pharmacological inhibition of EZH2 disrupts the female germline epigenome.Clinical epigenetics · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 1 country.
Funding
Abstract
backgroundAs with many anti-cancer drugs, the topoisomerase II inhibitor etoposide is considered safe for administration to women in the second and third trimesters of pregnancy, but assessment of effects on the developing fetus have been limited. The purpose of this research was to examine the effect of etoposide on germ cells in the developing ovary. Mouse ovary tissue culture was used as the experimental model, thus allowing us to examine effects of etoposide on all stages of germ cell development in the same way, in vitro.
resultsFetal ovaries from embryonic day 13.5 CD1 mice or neonatal ovaries from postnatal day 0 CD1 mice were cultured with 50-150 ng ml(-1) or 50-200 ng ml(-1) etoposide respectively, concentrations that are low relative to that in patient serum. When fetal ovaries were treated prior to follicle formation, etoposide resulted in dose-dependent damage, with 150 ng ml(-1) inducing a near-complete absence of healthy follicles. In contrast, treatment of neonatal ovaries, after follicle formation, had no effect on follicle numbers and only a minor effect on follicle health, even at 200 ng ml(-1). The sensitivity of female germ cells to etoposide coincided with topoisomerase IIα expression: in the developing ovary of both mouse and human, topoisomerase IIα was expressed in germ cells only prior to follicle formation.
conclusionsExposure of pre-follicular ovaries, in which topoisomerase IIα expression was germ cell-specific, resulted in a near-complete elimination of germ cells prior to follicle formation, with the remaining germ cells going on to form unhealthy follicles by the end of culture. In contrast, exposure to follicle-enclosed oocytes, which no longer expressed topoisomerase IIα in the germ cells, had no effect on total follicle numbers or health, the only effect seen specific to transitional follicles. Results indicate the potential for adverse effects on fetal ovarian development if etoposide is administered to pregnant women when germ cells are not yet enclosed within ovarian follicles, a process that starts at approximately 17 weeks gestation and is only complete towards the end of pregnancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.